JOHAN WILLEM MOUTON MEMORIAL SESSION - Challenges in using PK/PD and TDM for dose optimisation
Monday, July 12, 2021
5. New antibacterial agents, PK/PD & Stewardship, 1,5-hour Symposium
5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring
•
2406
•
8:30 AM
>
10:00 AM
•
JOHAN WILLEM MOUTON MEMORIAL SESSION - Challenges in using PK/PD and TDM for dose optimisation
•
5. Antimicrobials & stewardship
5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring
Therapeutic drug monitoring (TDM) and individualised dosing of antibiotics, including prolonged or continuous infusion, is increasingly used in many hospitals to enhance the chances of clinical cure while reducing the risk of toxicity. Especially for beta-lactam antibiotics, this approach is supported by studies showing that subtherapeutic concentrations are often achieved due to altered pharmacokinetics in this patient group. Still, there are uncertainties in which target drug levels are most appropriate, for which patients and drugs TDM should be used and practical aspects, e.g. stability of various antibiotics in solution. In this session, the underlying principles and evidence for PK/PD targets, and situations where TDM should be considered will be discussed. Also, practical aspects and challenges in ensuring adequate drug exposure with specific antibiotics will be reviewed.
8:30 AM
•
2406-1
•
PK/PD models: do they work with hypermutable/heteroresistant strains?
>
C.
Cornelia
LANDERSDORFER (Parkville)
8:50 AM
•
2406-2
•
When %TMIC is not enough: model-based dosing to better predict optimal dosing of selected antibiotics
>
E.
Elisabet
NIELSEN (Uppsala)
9:10 AM
•
2406-3
•
PK/PD of innovative treatment response markers
>
C.
Coen
VAN HASSELT (Leiden)
9:30 AM
•
2406-4
•
For which antibiotics, patients and infections should we consider TDM?
>
A.
Angela
HUTTNER (Geneva)
9:50 AM
•
2406-5
•
Q&A/Discussion
|